AR059887A1 - Compuestos pirazolicos heterobiciclicos, composiciones farmaceuticas que los contienen, y usos en trastornos hiperproliferativos, tales como cancer - Google Patents

Compuestos pirazolicos heterobiciclicos, composiciones farmaceuticas que los contienen, y usos en trastornos hiperproliferativos, tales como cancer

Info

Publication number
AR059887A1
AR059887A1 ARP070100948A ARP070100948A AR059887A1 AR 059887 A1 AR059887 A1 AR 059887A1 AR P070100948 A ARP070100948 A AR P070100948A AR P070100948 A ARP070100948 A AR P070100948A AR 059887 A1 AR059887 A1 AR 059887A1
Authority
AR
Argentina
Prior art keywords
alkyl
cr14r15
aryl
heteroaryl
nr10r11
Prior art date
Application number
ARP070100948A
Other languages
English (en)
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AR059887A1 publication Critical patent/AR059887A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Reivindicacion 1: Un compuesto seleccionado de las Formulas (1a) y (1b): y sus sales aceptables para uso farmacéutico, donde: X es O, S o NR10; Z2 y Z3 se seleccionan independientemente de CR4 y N, donde cero o uno de Z2 y z3 es N, R1 es H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, C(=O)NR10R11 o -(CR14R15)tNR10R11, o R1 es carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo y heteroarilo están opcionalmente sustituidos con uno más grupos independientemente seleccionados entre F, Cl, Br, I, CN, CF3, oxo, -OR10, SR10, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -(CR14R15)n-NR10R11, -NR10C(=Y)R13, -NR10C(=Y)OR11, -NR12C(=Y)NR10R11, - NR12SO2R10, -OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, -OS(O)2(OR10), -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -S(O)R10, -S(O)2R10, -S(O)2R10R11, -S(O)(OR10), -S(O)2(OR10), -SC(=Y)R10, -SC(=Y)OR10, -SC(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20, arilo C6-20, heteroarilo C1-20, -(CR14R15)-NR12C(=O)(CR14R15)NR10R11 y (CR14R15)tNR10R11, o R1 es NRxRY; R2 es H, CF3, CN, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, -C(=O)NR12(CR14R15)tNR10R11, -SR10, - S(O)R10, -S(O)2R10, S(O)2NR10R11, -SC(=Y)R10, -SC(=Y)OR10, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, C6-20 arilo, o heteroarilo C1-20, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroariloestán opcionalmente sustituidos con uno o más grupos independientemente seleccionados de F, Cl, Br, I, (CH2)nOR10, (CH2)nNR10R11, heteroarilo y heterociclilo; R3 es carbociclilo C3-12, heterociclilo C2-20, arilo C6- 20 o heteroarilo, donde dicho carbociclilo, heterociclilo, arilo y heteroarilo están opcionalmente sustituidos con uno o más grupos independientemente seleccionados de F, Cl, Br, I, CN, CF3, OR10, SR10, -C(=Y)R10, -C(=Y)OR10, -C(=Y)NR10R11, - NR10R11, -NR10C(=Y)R13, -NR10C(=Y)OR11, -NR12C(=Y)NR10R11, -NR12C(=O)C(=O)R10R11, -NR12C(=O)C(=O)Ora, -NR12SO2R10, -NR12C(=Y1)(CR14R15)nC(=Y2)NR10R11, -NR12C(=Y1)NR10C(=Y2)(CR14R15)nR11, -NR12C(=Y1)(CR14R15)nC(=Y2)-(CR14R15)mR10, -OC(=Y)R10, - OC(=Y)OR10, -OC(=Y)NR10R11, -OS(O)2(OR10), -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -S(O)(OR10), -S(O)2(OR10), -SC(=Y)R10, -SC(=Y)OR10, -SC(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3- 12, heterociclilo C2-20, arilo C6-20 y heteroarilo C1-20, donde dicho alquilo, alquenilo, alquinilo, cicloalquilo, heterociclilo, arilo y heteroarilo están opcionalmente sustituidos con uno o más grupos independientemente seleccionados de F, Cl, Br, I, OH, alquilo C1-12, NR10R11, y (CR14R15)n-arilo; R4 es H, F, Cl, Br, CF3, CN, -C(=Y )OR10, -C(=Y)NR10r11, -NR10R11, NR10C(=Y)R11, NR10C(=Y)OR11, NR12C(=Y)NR10R11, NR12SO2NR10R11, -OR10, -OC(=Y)R10, -OC(=Y)OR10, -OC(=Y)NR10R11, - C(=O)NR12(CR14R15)tNR10R11, -OP(=Y)(OR10)(OR11), -OP(OR10)(OR11), -SR10, -S(O)R10, -S(O)2R10, -S(O)2NR10R11, -SC(=Y)R10, -SC(=Y)OR10, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 o heteroarilo C1-20; R10, R11 y R12 son independientemente H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterocicliclo (CR14R15)nC2-20, arilo (CR14R15)nC6-20, o heteroarilo C1-20, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroarilo están opcionalmente sustituidos con uno o más grupos independientemente seleccionados de F, Cl, Br I, SO2Rc, CN, Ora, NRaRb, C(=O)NRaRb, CRaC(=O)Rb, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3- 12, arilo C6-20 y heteroarilo C1-20, o R10 y R11 junto con el nitrogeno al cual están unidos opcionalmente forman un anillo heterocíclico C3-20 saturado, parcialmente insaturado o completamente insaturado que contiene uno o más átomos anulares adicionales seleccionados entre N, O o S, donde dicho anillo heterocíclico esta opcionalmente sustituido con uno o más grupos seleccionados independientemente entre oxo, (CH2)nORa, NRaRb, CF3, F, Cl, Br, I, SO2Ra, C(=O)Ra, NR10C(=Y)R11, C(=Y)NR10R11, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterocicliclo C2-20 y arilo C6-20 y heteroarilo C1-20, o R10 y r12 junto con los átomos a los cuales están unidos forman un anillo heterocíclico C3-20 sustituido con oxo opcionalmente fusionado con un anillo bencénico; R13 es H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, (CR14R15)n-cicloalquilo, (CR14R15)n-heterociclilo, (CR14R15)n-arilo, (CR14R15)n-heteroarilo, (CR14R15)n-O-(CR14R15)m-arilo, (CR14R15)n-O- (CR14R15)m-arilo, (CR14R15)n-OR10, (CR14R15)n-NR10R11, (CR14R15)n-NR10C(=O)R11, o (CR14R15)n-NR10(SO2Me)-R11, donde dichas porciones alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, y heteroarilo están opcionalmente sustituidas con uno o más grupos independientemente seleccionados de F, Cl, Br, I, oxo, SO2Rc, CN, ORa, C(=O)Ra, C(=O)ORa, NRaRb, NRaC(=O)Rb, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20 y arilo C6-20 y heteroarilo C1-20, cada R14 y R15 es independientemente H, alquilo C1-12 o (CH2)t-arilo, o R14 y R15 junto con los átomos a los cuales están unidos forman un anillo carbocíclico C3-12 saturado o parcialmente saturado, o R10 y R15 junto con los átomos a los cuales están unidos forman un anillo heterocíclico monocíclico o bicíclico saturado o parcialmente insaturado sustituido con oxo también opcionalmente sustituido con uno más grupos independientemente seleccionados entre F, Cl, Br, I, ORa, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-12, heterociclilo C2-20 y arilo C6-20 y heteroarilo C1-20, donde dicho alquilo y arilo están opcionalmente sustituidos con uno o más grupos independientemente seleccionados de F, Cl, Br, y I, o R14 es cero y R10 y R15 junto con los átomos a los cuales están unidos forman un anillo heteroarilo C1-20 que tiene uno o más heteroátomos; Ra y Rb son independientemente H, alquilo C1-12, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, heterociclilo C2-20, arilo C6-20 y heteroarilo C1-20, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, heterociclilo, arilo, y heteroarilo están opcionalmente sustituidos con uno o más grupos alquilo C1-6; Rc es alquilo C1-12 o arilo C6-20, donde dicho alquilo y arilo estánm opcionalmente sustituidos con uno o más grupos independientemente seleccionados de F, Cl, Br, I, ORa y C(=O)NRaRb; Rx es H o alquilo C1-6; Ry es (i) (alquilo C1-6)NRjRk donde Fj y Rk son independientemente H o alquilo C1-6; (ii) cicloalquilo opcionalmente sustituidos con OH u -OC(=O)CF3; o (iii) un anillo heterocíclico de 5-6 miembros que tiene 1 a 2 heteroátomos del anillo independientemente seleccionados entre N y O y opcionalmente sustituidos con un grupo halogeno, alquilo C1-6, (alquilo C1-6)OH, (alquilo C1-6)O(alquilo C1-6), o fluoroalquilo C1-6; Y, Y1 e Y2 son independientemente O o S; t es 1, 2, 3, 4, 5 o 6; y n y m son independientemente 0, 1, 2, 3, 4, 5 o 6.
ARP070100948A 2006-03-07 2007-03-07 Compuestos pirazolicos heterobiciclicos, composiciones farmaceuticas que los contienen, y usos en trastornos hiperproliferativos, tales como cancer AR059887A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77980506P 2006-03-07 2006-03-07
US87483206P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
AR059887A1 true AR059887A1 (es) 2008-05-07

Family

ID=38475465

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100948A AR059887A1 (es) 2006-03-07 2007-03-07 Compuestos pirazolicos heterobiciclicos, composiciones farmaceuticas que los contienen, y usos en trastornos hiperproliferativos, tales como cancer

Country Status (20)

Country Link
US (2) US7723330B2 (es)
EP (1) EP2001880A2 (es)
JP (1) JP2009529047A (es)
KR (1) KR20080110783A (es)
AR (1) AR059887A1 (es)
AU (1) AU2007224020A1 (es)
BR (1) BRPI0708615A2 (es)
CA (1) CA2645137A1 (es)
CL (1) CL2007000601A1 (es)
CO (1) CO6140061A2 (es)
CR (1) CR10338A (es)
EC (1) ECSP088791A (es)
IL (1) IL193587A0 (es)
MA (1) MA31339B1 (es)
MX (1) MX2008011220A (es)
NO (1) NO20084183L (es)
RU (1) RU2008139599A (es)
TW (1) TW200800996A (es)
WO (1) WO2007103308A2 (es)
ZA (1) ZA200807632B (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE432357T1 (de) * 2002-01-22 2009-06-15 Biomatera Inc Verfahren zur trocknung von biologisch abbaubaren polymeren
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
PT2004654E (pt) 2006-04-04 2013-08-27 Univ California Derivados de pirazolopirimidina para utilização como antagonistas da quinase
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
AU2007286345B2 (en) * 2006-08-16 2012-03-08 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US7776857B2 (en) * 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
CN109970759A (zh) 2007-08-29 2019-07-05 梅特希尔基因公司 蛋白酪氨酸激酶活性的抑制剂
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
MY159955A (en) 2008-01-04 2017-02-15 Intellikine Inc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5608097B2 (ja) 2008-01-08 2014-10-15 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害薬としてのピロロピリジン
CN101965347B (zh) 2008-01-09 2013-01-02 阵列生物制药公司 作为激酶抑制剂的吡唑并吡啶
EP2235001B1 (en) 2008-01-23 2014-12-24 Bristol-Myers Squibb Company Process for preparing pyridinone compounds
WO2009095752A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Fused pyrazole derivatives as cannabinoid receptor modulators
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US8551989B2 (en) * 2008-06-09 2013-10-08 Bayer Intellectual Property Gmbh Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof
CA2727199C (en) * 2008-06-09 2016-11-22 Bayer Schering Pharma Aktiengesellschaft Annellated 4-(indazolyl)-1,4-dihydropyridine derivatives and methods of use thereof
KR20110039326A (ko) 2008-07-08 2011-04-15 인텔리카인, 인크. 키나제 억제제 및 사용 방법
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
TWI365185B (en) * 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
CA2740746A1 (en) * 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
SG196855A1 (en) 2008-10-22 2014-02-13 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US20130197230A1 (en) * 2008-11-13 2013-08-01 Jo Ann Wilson Methods of preparing quinoline derivatives
PL2387563T5 (pl) 2009-01-16 2023-03-13 Exelixis, Inc. Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011049987A2 (en) * 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
WO2011109232A1 (en) * 2010-03-01 2011-09-09 Novadrug, Llc Compositions and methods for treating viral diseases
US8569319B2 (en) 2010-04-29 2013-10-29 Deciphera Pharmaceuticals, LLS Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
PT3205654T (pt) 2010-05-20 2019-04-22 Array Biopharma Inc Compostos macrocíclicos como inibidores de cinases trk
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101875720B1 (ko) 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
JP5707518B2 (ja) 2011-02-28 2015-04-30 カリトル サイエンシズ， エルエルシー 置換型キノリン化合物及び使用方法
WO2012127472A1 (en) * 2011-03-22 2012-09-27 Mapi Pharma Ltd. Process and intermediates for the preparation of preladenant and related compounds
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
WO2013022519A1 (en) * 2011-08-10 2013-02-14 Merck Patent Gmbh Pyrido-pyrimidine derivatives
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
SG11201400724SA (en) 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
RU2501800C2 (ru) * 2012-02-07 2013-12-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" 2-(6-АРИЛ-4-АРОИЛ-3-МЕТИЛ-1-ФЕНИЛ-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-5-ИЛ)-2-ОКСО-N-АРИЛАЦЕТАМИДЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
EA201500402A1 (ru) 2012-11-08 2016-05-31 Пфайзер Инк. Гетероароматические соединения в качестве лигандов допамина d1
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA121104C2 (uk) 2013-10-04 2020-04-10 Інфініті Фармасьютикалз, Інк. Гетероциклічні сполуки і їх застосування
PL3087070T3 (pl) * 2013-12-26 2018-03-30 Ignyta, Inc. Pochodne pirazolo[1,5-a]pirydyny i sposoby ich zastosowania
ES2913486T3 (es) 2014-03-19 2022-06-02 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para la utilización en el tratamiento de trastornos mediados por PI3K-gamma
MA39776A (fr) 2014-03-24 2017-02-01 Hoffmann La Roche Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016004272A1 (en) * 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI767858B (zh) 2014-11-16 2022-06-11 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
WO2016130818A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CN108290827B (zh) 2015-07-31 2021-01-01 约翰霍普金斯大学 谷氨酰胺类似物的前药
MX2018003058A (es) 2015-09-14 2018-08-01 Infinity Pharmaceuticals Inc Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
JP2018530557A (ja) * 2015-10-09 2018-10-18 アッヴィ・エス・ア・エール・エル 置換ピラゾロ［３，４−ｂ］ピリジン−６−カルボン酸およびこの使用
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN108431009A (zh) 2015-10-27 2018-08-21 默沙东公司 作为RORγT抑制剂的取代的吲唑化合物及其用途
AU2016344118A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102400423B1 (ko) 2016-04-04 2022-05-19 록쏘 온콜로지, 인코포레이티드 (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-하이드록시피롤리딘-1-카복사미드의 액체 제형
LT3800189T (lt) 2016-05-18 2023-10-10 Loxo Oncology, Inc. (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas
PL3464272T3 (pl) 2016-06-07 2022-03-28 Jacobio Pharmaceuticals Co., Ltd. Nowe pochodne heterocykliczne użyteczne jako inhibitory SHP2
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
CN108948002A (zh) * 2017-05-19 2018-12-07 厦门大学 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
WO2018228923A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
EP3638671A1 (en) 2017-06-13 2020-04-22 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2018228920A1 (en) 2017-06-13 2018-12-20 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CA3070013A1 (en) 2017-07-18 2019-01-24 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2019121143A1 (en) 2017-12-20 2019-06-27 Basf Se Substituted cyclopropyl derivatives
JP7253498B2 (ja) 2017-12-22 2023-04-06 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除剤
US11673897B2 (en) 2018-01-26 2023-06-13 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
US11708367B2 (en) 2018-01-26 2023-07-25 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶２介導的傳訊之抑制劑
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP2022537833A (ja) * 2019-06-24 2022-08-30 ベネボレントエーアイ バイオ リミティド 新規化合物と方法
US20220289679A1 (en) * 2019-07-29 2022-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP4069212A4 (en) * 2019-12-04 2024-03-06 Arcus Biosciences, Inc. HIF-2 ALPHA INHIBITORS
US20230150956A1 (en) * 2020-02-10 2023-05-18 Stemsynergy Therapeutics, Inc. Myc inhibitors and uses thereof
WO2023137406A1 (en) * 2022-01-12 2023-07-20 Shenzhen Ionova Life Science Co., Ltd. Heteroaryl compounds as hpk1 inhibitors and methods of using same
TW202413341A (zh) 2022-09-23 2024-04-01 美商富曼西公司 吡唑醯胺殺昆蟲劑

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ZW12187A1 (en) 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
AU3262593A (en) 1992-01-11 1993-08-03 Schering Agrochemicals Limited Biheterocyclic fungicidal compounds
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
EP0765327B1 (en) 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2264220A1 (en) 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
CA2266519C (en) * 1996-10-02 2007-01-23 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
JP2002508324A (ja) 1997-12-13 2002-03-19 ブリストル−マイヤーズ スクイブ カンパニー サイクリン依存性キナーゼ阻害剤としてのピラゾロ［３，４−ｂ］ピリジンの使用
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
EP1212327B8 (en) * 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines as therapeutic agents
CA2407445A1 (en) 2000-04-25 2001-11-01 Bristol-Myers Squibb Company Use of 5-thio-, sulfinyl- and sulfonylpyrazolo¬3,4-b|-pyridines as cyclin dependent kinase inhibitors
WO2001098301A1 (fr) 2000-06-20 2001-12-27 Japan Tobacco Inc. Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
PE20030062A1 (es) 2001-05-30 2003-02-08 Sugen Inc Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
EP2258366B1 (en) 2001-06-22 2013-04-03 Kirin Pharma Kabushiki Kaisha Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
ATE355293T1 (de) 2001-09-12 2006-03-15 Pharmacia & Upjohn Co Llc Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
AU2002357193A1 (en) 2001-12-19 2003-07-09 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
JP4508650B2 (ja) 2002-01-29 2010-07-21 グラクソ グループ リミテッド アミノピペリジン化合物、当該化合物の製法および当該化合物を含有する医薬組成物
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
US7186716B2 (en) * 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
JP2006503108A (ja) 2002-09-16 2006-01-26 グラクソ　グループ　リミテッド ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004031184A1 (en) 2002-10-01 2004-04-15 Johnson & Johnson Pharmaceutical Research & Development, Inc. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
TW200427688A (en) 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
EP2476667B1 (en) 2003-02-26 2014-07-16 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US7547794B2 (en) 2003-04-03 2009-06-16 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
US20060009493A1 (en) 2003-07-02 2006-01-12 Sugen, Inc. Indolinone hydrazides as c-Met inhibitors
AR045342A1 (es) 2003-08-15 2005-10-26 Merck & Co Inc Inhibidores de quinesina mitotica
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
CA2557004A1 (en) 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
ATE455765T1 (de) 2003-12-22 2010-02-15 Basilea Pharmaceutica Ag Aryloxy- und arylthioxyacetophenon-verbindungen zur behandlung von krebs
CN1933839A (zh) 2004-01-23 2007-03-21 安进公司 化合物和使用方法
KR100843526B1 (ko) * 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 피라졸의 접합 유도체
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
CA2603876A1 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl nmda/nr2b antagonists
US7470693B2 (en) 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US8093264B2 (en) 2005-05-20 2012-01-10 Methylgene Inc. Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007103308A2 (en) * 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
AR060061A1 (es) 2006-03-22 2008-05-21 Methylgene Inc Inhibidores de la actividad de la proteina tirosina quinasa
CA2680625C (en) * 2007-03-14 2016-02-23 Ranbaxy Laboratories Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
KR101610415B1 (ko) * 2007-12-21 2016-04-07 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물

Also Published As

Publication number Publication date
JP2009529047A (ja) 2009-08-13
IL193587A0 (en) 2009-08-03
WO2007103308A2 (en) 2007-09-13
MX2008011220A (es) 2008-09-11
BRPI0708615A2 (pt) 2011-06-07
KR20080110783A (ko) 2008-12-19
MA31339B1 (fr) 2010-05-03
ECSP088791A (es) 2008-11-27
CA2645137A1 (en) 2007-09-13
RU2008139599A (ru) 2010-04-20
CR10338A (es) 2008-10-31
US20100256356A1 (en) 2010-10-07
WO2007103308A3 (en) 2008-02-07
CO6140061A2 (es) 2010-03-19
TW200800996A (en) 2008-01-01
CL2007000601A1 (es) 2008-01-25
ZA200807632B (en) 2011-04-28
US20070238726A1 (en) 2007-10-11
US7723330B2 (en) 2010-05-25
NO20084183L (no) 2008-11-24
AU2007224020A1 (en) 2007-09-13
EP2001880A2 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
AR059887A1 (es) Compuestos pirazolicos heterobiciclicos, composiciones farmaceuticas que los contienen, y usos en trastornos hiperproliferativos, tales como cancer
AR059246A1 (es) Compuestos heterobiciclicos de tiofeno y metodos de uso
PE20171240A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
PE20190509A1 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
AR079689A1 (es) Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias.
AR060632A1 (es) Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso
AR063318A1 (es) Pirazoliltienopiridinas terapeuticas
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
AR070521A1 (es) Derivados de 4h-pirido[4,3-d]-pirimidin-4-ona,inhibidores de quinasas,composiciones farmaceuticas que los contienen,uso de los mismos para el tratamiento de enfermedades con proliferacion celular o autoinmunes y metodo de preparacion de intermediarios de sintesis .
AR062785A1 (es) Compuestos de 4-metilpiridopirimidinona, composiciones farmaceuticas que los contienen y usos en estados patologicos asociados al crecimiento anormal celular,tal como cancer.
PE20060185A1 (es) ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
AR093339A1 (es) Analogos de spliceostatina y metodos para su preparacion
AR062122A1 (es) Agonistas del subtipo ep2 del receptor de prostaglanina e
AR076810A1 (es) Compuestos anticancerigenos de amino pirimidina
AR048501A1 (es) Compuesto de benzoazabicicloheptano dimerico, composicion farmaceutica que lo comprende y su uso para prepararla
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
PE20161366A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo
AR094684A1 (es) Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih
GB0507601D0 (en) Compounds
PE20110196A1 (es) 5-alquinil-pirimidinas
AR085398A1 (es) Ureas asimetricas y usos medicos de las mismas
AR071592A1 (es) Fenoxibenzamidas sustituidas
AR049121A1 (es) Compuestos quimicos que contienen anillos de oxazolidinona e isoxazolina sustituida

Legal Events

Date Code Title Description
FB Suspension of granting procedure